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Introduction
Targeted therapy has become increasingly important in the treat-
ment of several solid tumour types such as colorectal cancer,
breast cancer, renal cell carcinoma, head and neck cancer and lung
cancer. The search for biologic characteristics determining the
response to these agents is of great interest. This requires the
development of new diagnostic tools and biomarkers. The selec-
tion of patients that are likely to benefit from targeted treatment
will ultimately result in a more optimal patient outcome and a
reduction of toxicity and costs. Several biomarkers have already
been identified, such as overexpression of the gene encoding
HER2 (ERBB2) as a predictor for the response to trastuzumab 
(a HER2 monoclonal antibody) in breast cancer [1], and an acti-
vating KIT mutation in gastrointestinal stromal tumours mediating
the response to imatinib [2].
Involvement of the epidermal growth factor receptor (EGFR)
signalling pathway has been identified in several cancer types.
Binding of a ligand (EGF, transforming growth factor-, epiregulin,
amphiregulin) to the receptor induces dimerization and autophos-
phorylation and subsequent stimulation of several intracellular
signalling pathways such as the RAS/RAF/MAPK pathway and the
phosphoinositide-3 kinase (PI3K) pathway. This ultimately results
in the stimulation of cell cycle progression, proliferation, 
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Abstract
The KRAS mutation status predicts the outcome of treatment with epidermal growth factor receptor targeted agents, and therefore the
testing for KRAS mutations has become an important diagnostic procedure. To optimize the quality of this test, we compared the results
of the two most commonly used KRAS mutation tests, cycle sequencing and a real-time PCR-based assay, in DNA extracted from for-
malin-fixed paraffin-embedded (FFPE) colorectal cancer samples of 511 patients. The results were interpreted in the context of the
tumour cell percentage and the assay parameters. In 510 samples KRAS mutation status assessment was successful. A KRAS mutation
was detected in 201 tumours (39.4%). Sequencing and the real-time PCR-based assay generated the same result in 486 samples
(95.3%). The sequencing result was considered false positive in one (0.2%) and false negative in nine samples (1.8%). The assay result
was considered false positive in six (1.2%) and false negative in seven samples (1.4%). Explanations for discrepant test results were a
higher sensitivity of the assay in samples with a low tumour cell percentage, occurrence of mutations that are not covered by the assay
and  Ct values approximating the cut-off value of the assay. In conclusion, both sequencing and the real-time PCR-based assay are reli-
able tests for KRAS mutation analysis in FFPE colorectal cancer samples, with a sensitivity of 95.5% (95% confidence interval [CI]
91.7–97.9%) and 96.5% (95% CI 93.0–98.6%), respectively. The real-time PCR based assay is the method of choice in samples with a
tumour cell percentage below 30%.
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angiogenesis and the inhibition of apoptosis [3]. Several drugs
targeting the EGFR have shown a clinical benefit in cancer patients
and have been approved for the use in clinical practice. KRAS
encodes the KRAS protein which is involved in the MAPK
signalling  pathway. An oncogenic mutation in KRAS results in
constitutive activation of the RAS/RAF signalling pathway inde-
pendent from EGFR activation by binding of the ligand [4].
Patients with advanced colorectal cancer and a tumour harbouring
a KRAS codon 12 or 13 mutation are resistant to treatment with
the EGFR monoclonal antibodies cetuximab [5–9] and panitu-
mumab [10]. Therefore, the European Medicines Agency has
restricted the use of these antibodies to patients with wild-type
KRAS tumours.
KRAS mutations are observed in approximately 38% of
 colorectal tumours [11]. Seven specific mutations in codon 12
(c.34GA [p.Gly12Ser], c.34GT [p.Gly12Cys], c.34GC
[p.Gly12Arg], c.35GA [p.Gly12Asp], c.35GT [p.Gly12Val],
c.35GC [p.Gly12Ala]) and 13 (c.38GA [p.Gly13Asp]) comprise
approximately 96% of the observed KRAS mutations whereas
mutations in codon 61 comprise about 3% of the mutations [12].
Whether other than codons 12 and 13 mutations result in similar
resistance to EGFR monoclonal antibodies remains to be
assessed.
Given its important role for the selection of patients for anti-
EGFR treatment, the number of patients in whom the assessment
of the KRAS mutation status is indicated is increasing. Until
recently sequencing was the most common method for KRAS
mutation analysis. Recently, a real-time PCR-based assay target-
ing only the seven most prevalent KRAS mutations in codons 
12 and 13 has become commercially available (DxS, Manchester,
UK). Clinical studies already use a real-time PCR-based assay 
[6, 10, 13] but the assay has not been directly compared with
sequencing. Although several different techniques to detect KRAS
mutations are available [14], international guidelines for the per-
formance and interpretation of KRAS mutation analyses are still to
be developed [15]. In this study we compare the performance of
a cycle sequencing approach with dye terminators of the region
surrounding KRAS codons 12 and 13 and the commercially
 available real-time PCR-based assay using formalin-fixed paraffin-
embedded (FFPE) colorectal cancer tissue from a randomized
 clinical trial, and give recommendations for interpretation of the
KRAS test results obtained with both approaches.
Materials and methods
Selection of tumour material
Suitable tumour samples from 511 primary tumours were collected from
755 patients with previously untreated advanced colorectal cancer who
participated in a multicentre phase 3 study (CAIRO2, CKTO 2005–02) of
the Dutch Colorectal Cancer Group, and who were treated with
capecitabine, oxaliplatin and bevacizumab, with or without cetuximab 
[16, 17]. The written informed consent required for all patients before
study entry also included translational research on tumour tissue. The
samples were collected from more than 50 different laboratories of pathol-
ogy. The histology of all tumour samples was centrally reviewed by a
pathologist (I.D.N., J.H.J.M.v.K.). Of 244 patients no suitable tumour 
tissue was available, because no resection of the primary tumour was 
performed (n  164), the amount of available tissue was too low for DNA
isolation (n  10), the tissue was received too late to be included in this
analysis (n  17), the patient was excluded from all analyses due to ineli-
gibility to the study protocol (n  19), or no material was made available
for this study (n  34).
DNA extraction
Genomic DNA was extracted from four to eight manually microdissected
50-m sections of FFPE tissue. Four micrometre haematoxylin-stained tis-
sue sections, obtained before and after the withdrawal of the 50-m sec-
tions, were used to estimate the tumour cell percentage in the microdis-
sected tumour specimen. DNA was extracted as previously described [18].
After the ProtK incubation, RNA-free genomic DNA was obtained by adding
10 l RNase A (100 mg/ml, Qiagen, West Sussex, UK) for 1 hr at 37C.
Further DNA isolation was performed according to the manufacturer’s pro-
tocol (DNeasy blood and tissue kit, Qiagen), except for the wash step with
500 l buffer AW2 which was repeated once. DNA was eluted in 50 l AE
buffer (provided by the Qiagen kit). DNA concentration was determined at
260 nm using the Nanodrop ND-1000 spectrophotometer (Nanodrop
Technologies, Inc., Wilmington, DE, USA).
Multiplex control PCR
DNA quality was assessed by performing a multiplex PCR using four
primer sets, resulting in fragments of 100, 200, 300 and 400 base pairs
(bp) [19]. A 50 l reaction mixture contained 50 ng DNA; 0.2 M of each
primer (Invitrogen, Paisley, UK); dATP, dCTP, dGTP, dTTP 
(GE Healthcare, Piscataway, NJ, USA) at 500 mM each; 50 mM KCl; 10 mM
Tris-HCl (pH 8.3); 2 mM MgCl2 (Applied Biosystems, Foster City, CA, USA)
and 1 U AmpliTaq Gold (Applied Biosystems). The PCR conditions were as
follows: 94C for 10 min.; 92C for 30 sec., 60C for 40 sec., 72C for 
40 sec. (35 cycles) and 72C for 30 min.
The PCR products were analysed on a 2% agarose gel containing 
0.3 g/ml ethidium bromide (Sigma, St Louis, MO, USA). DNA 
quality classification was based on the largest of the four possible 
fragments detected.
KRAS mutation analysis by dye 
terminator cycle sequencing
A 50 l reaction mixture, containing the oligonucleotide primers KRAS-F and
KRAS-R (Invitrogen) at 0.2 M each; dATP, dCTP, dGTP, and dTTP 
(GE Healthcare) at 500 M each; 50 mM KCl; 10 mM Tris-HCl (pH 8.3); 2.5
mM MgCl2; 1 U of AmpliTaq Gold polymerase (Applied Biosystems); and 50
ng of template DNA, was used to generate a 198 bp PCR product of the KRAS
gene (GenBank accession number NM_004985). The PCR conditions were as
follows: 94C for 10 min.; 92C for 1 min., 60C for 45 sec., 72C for 
45 sec. (35 cycles); and 72C for 10 min. PCR products were purified with the
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MinElute 96 UF PCR Purification Kit (Qiagen) and subsequently used for
sequencing with fluorescently labelled terminators (BigDye® Terminators 
(v 1.1); Applied Biosystems) with both the M13-F and M13-R sequencing
primers. The following primers were used for KRAS amplification:
5	-TGTAAAACGACGGCCAGTGGTACTGGTGGAGTATTTGATAGTG-3	
(forward) and 5	-CAGGAAACAGCTATGACCTGGATCATATTCGTCCACAAAA-
3	 (reverse). The nucleotides presented in italic correspond to M13
 consensus sequences and were used for the cycle sequencing with M13
consensus primers.
The sequencing products were analysed on an ABI 3730 DNA Analyzer
(Applied Biosystems) and the data analysis was performed with
Sequencing Analysis Software Sequencing Analysis Software v5.3.1 with
KBTM Basecaller. Sequence results were scored by visual inspection of the
chromatograms.
KRAS mutation analysis using 
the real-time PCR-based assay
In this study we used a commercially available real-time PCR-based assay
for KRAS mutation detection (DxS) which combines the ARMS® and
Scorpions® technique to identify the seven following KRAS mutations,
located in codon 12 and 13: c.34GA (p.Gly12Ser), c.34GT
(p.Gly12Cys), c.34GC (p.Gly12Arg), c.35GA (p.Gly12Asp),
c.35GT(p.Gly12Val), c.35GC (p.Gly12Ala) and c.38GA (p.Gly13Asp).
In a real-time or quantitative PCR the amount of product is monitored dur-
ing the reaction. The number of amplification cycles required to obtain a
certain amount of PCR product is registered as the threshold cycle (Ct)
[20]. A mutation is present when the  Ct (which is the Ct of the mutation
specific PCR minus the Ct of a PCR of an endogenous control gene) is
below a mutation specific threshold. The  CT values that were used as a
cut-off level for the presence of a KRAS mutation were based on the detec-
tion of at least 1% tumour cells and were provided by the manufacturer of
the kit. This  Ct cut-off values were as follows for the different mutations:
c.34GA cut-off 9, c.34GT cut-off 7, c.34GC cut-off 8, c.35GA 
cut-off 8, c.35GT cut-off 6.5, c.35GC cut-off 6.5 and c.38GA 
cut-off 9. The assay was validated for analytical and diagnostic use and
performed according to manufacturer’s instructions on a 7500 Fast Real-
Time PCR System (Applied Biosystems). The exact location of the primers
used in this kit is not available. The amount of input DNA was based on
both the concentration of isolated DNA and the quality of DNA, as 
determined by the multiplex control PCR. Duplicate analyses were only
performed in case of a discrepancy between the result of the sequencing
and the assay.
Statistical analysis
The tumour cell percentages in previously irradiated tumours com-
pared to not irradiated tumours was compared using a Wilcoxon rank
sum test. The correlations between poor DNA quality and previous
radiotherapy, between a low tumour cell percentage and previous
radiotherapy, and between a low tumour cell percentage and KRAS
mutation frequency were calculated using a Fisher’s exact test. All
tests were performed two-sided with a  significance level of 0.05. The
statistical tests were performed with SPSS version 16.0 (SPSS, Inc,,
Chicago, IL, USA).
Results
Sample description
FFPE colorectal cancer tissue was obtained from 511 patients. The
baseline characteristics of these patients were comparable with
the total study population (data not shown). The median DNA frag-
ment length was 300 bp (range 100–400 bp). Forty samples
(7.8%) contained poor quality DNA (less than 200 bp on the
 multiplex control PCR). Poor DNA quality was not associated with
previous radiotherapy on the primary tumour (10% poor quality
DNA in 110 irradiated tumours versus 7.2% in 390 not irradiated
tumours, P  0.32). The frequency of the different tumour cell
percentages as assessed on a haematoxylin-stained tissue section
is shown in Fig. 1A. The median tumour cell percentage was 60%
(range 3–90%). A low tumour cell percentage was associated with
previous radiotherapy on the primary tumour (Fig. 1B). In 109
previously irradiated tumours the median tumour cell percentage
was 40%, compared to 60% in 375 not irradiated tumours 
(P 
0.001). Ten samples (9.2%) of patients who received previ-
ous radiotherapy contained 10% or less tumour cells versus four
samples (1.1%) of patients without previous radiotherapy 
(P 
0.001). The radiotherapy status of 10 samples was unknown.
Consistency between sequencing 
and real-time PCR-based assay
In all 511 samples the KRAS mutation status was assessed
both by using sequencing and the real-time PCR-based assay.
In 486 samples (95.3%) the two test methods generated the
same outcome. In the discrepant samples both tests were
repeated and, providing the availability of sufficient tissue, new
DNA was isolated in which again KRAS mutation analysis was
performed.
Description of discrepant test results (Table 1)
In seven samples a mutation was detected by sequencing but not
by the assay (no. 1–7). In four of these samples in which a muta-
tion was only detected by sequencing, the duplicate analyses gen-
erated the same discrepant results (no. 1–4). In three cases the
mutations remained undetected by the real-time PCR-based assay
because these alterations were not targeted by the assay
(c.35_36delinsAG (p.Gly12Glu); c.38_39delinsAG (p.Gly13Glu);
c.[38GA; 40GA] (p.[Gly13Asp; Val14Ile]; no. 1–3). In the
fourth case a new DNA isolation did no longer reveal a mutation
by sequencing, thus the initial sequencing was considered false
positive due to a sample tracking problem (no. 4). In the other
three samples the second analysis with the kit confirmed the
sequencing results, and thus the kit was considered false negative
(no. 5–7).
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In one sample the mutation c.37GT (p.Gly13Cys), which
was found in duplicate by sequencing was detected as c.35GT
(p.Gly12Val) in the first and as wild-type in the second real-
time PCR experiment (no. 8). This rare mutation is not targeted
by the kit.
In 16 samples a mutation was detected by the assay and not by
sequencing. In eight of these samples the inconsistent results
were persistent in the second analyses. In one sample the muta-
tion probably remained below the detection limit of our sequenc-
ing method due to heterogeneity of the primary tumour, which
Fig. 1 (A) The number of samples per tumour cell percentage. (B) The frequency of irradiated (black bars) versus not irradiated tumours (grey bars)
according to tumour cell percentage. (C) The KRAS mutation frequency (with 5% confidence level) according to the final test result (black bars), accord-
ing to the sequencing results (grey bars) or the results with the real-time PCR-based assay (white bars) according to tumour cell percentage.
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Table 1 Description of 24 discrepant test results
No.
Tumour 
cell%
Sequence 1 Assay 1 Sequence 2 Assay 2
Sequence new
DNA 
Final interpreta-
tion
Test Explanation
1 80 c.35_36delinsAG wt c.35_36delinsAG wt c.35_36delinsAG c.35_36delinsAG FNA not targeted by assay
2 80 c.38_39delinsAG wt c.38_39delinsAG wt c.38_39delinsAG FNA not targeted by assay
3 90 [c.38G>A; 40G>A] wt [c.38G>A; 40G>A] wt [c.38G>A; 40G>A] [c.38G>A; 40G>A] FNA not targeted by assay
4 80 c.35G>A wt c.35G>A wt wt wt FPS
5 60 c.34G>T wt c.34G>T c.34G>T c.34G>T* c.34G>T FNA
6 50 c.35G>A wt c.35G>A c.35G>A c.35G>A* c.35G>A FNA
7 70 c.38G>A wt c.38G>A c.38G>A c.38G>A c.38G>A FNA
8 80 c.37G>T c.35G>T c.37G>T wt c.37G>T FNA not targeted by assay
9 70 wt c.35G>T wt c.35G>T wt/ c.35G>T# c.35G>T FNS heterogeneity
10 20 wt c.34G>C wt c.34G>C c.34G>C FNS low tumour cell%
11 20 wt c.35G>A wt c.35G>A c.35G>A** c.35G>A FNS low tumour cell%
12 10 wt c.35G>A wt c.35G>A c.35G>A* c.35G>A FNS low tumour cell%
13 20 wt c.35G>T wt c.35G>T c.35G>T FNS low tumour cell%
14 10 wt c.35G>T wt wt c.35G>T** c.35G>T FNS low tumour cell%
15 80 wt c.35G>A wt c.35G>A wt wt FPA high  Ct
16 50 wt c.35G>A wt wt wt FPA high  Ct
17 80 wt c.38G>A wt c.38G>A wt wt FPA high  Ct
18 30 wt c.38G>A wt wt wt wt FPA high  Ct
19 50 wt c.34G>T wt wt wt% wt FPA .
20 50 wt c.38G>A wt wt wt% wt FPA
21 80 wt c.34G>T c.34G>T c.34G>T c.34G>T FNS
22 50 wt c.35G>A c.35G>A c.35G>A c.35G>A c.35G>A FNS
23 50 wt c.35G>T c.35G>T c.35G>T c.35G>T c.35G>T FNS
24 10 wt c.38G>A wt c.38G>A Inconclusive
low tumour cell% and
high  Ct
*For the second DNA isolation tissue was derived from a different cube of the same tumour.
**For the second DNA isolation tissue derived from metastatic tissue was used with a higher tumour cell percentage.
#DNA isolated from two different regions of the tumour showed wild-type with sequencing and with the assay wild-type in one sample and a
c.35G>T mutation in another sample indicating intratumoral heterogeneity.
%In the newly isolated DNA the real-time PCR based assay also showed wild-type KRAS.
wt  wild-type.
FNA  false negative result assay.
FPS  false positive result sequencing.
FNS  false negative result sequencing.
FPA  false positive result assay.
Bold figures indicate difference in significance vs other columns.
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could be demonstrated by DNA isolation of two different regions
from the tumour (no. 9). In five other persistent cases (no. 10–13,
24) and in one case in which the assay was not consistently pos-
itive (no. 14), the tumour cell percentage was 20% or lower. Again
the mutation probably remained below the detection limit of our
sequencing method, which could be confirmed by analyses of a
second isolate with a higher tumour cell percentage in three cases
(no. 11, 12, 14). In two cases in which the assay was consistently
positive while sequencing was negative and in two other cases in
which only the first assay result was positive the  Ct approximated
Fig. 2  Ct in relation to tumour
cell percentage and true positive
(), false positive (*) and inclu-
sive () assay results with a fit
line plus 95% CI for the individ-
ual values. (A) Results for KRAS
c.35GA (p.Gly12Asp). For this
alteration the  Ct cut-off value
as provided by the manufacturer
of the kit was 8. (B) Results for
KRAS c.38GA (p.Gly13Asp).
For this alteration the  Ct cut-off
value as provided by the manu-
facturer of the kit was 9.
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the cut-off value as provided by the manufacturer of the assay
(c.35GA (p.Gly12Asp)  Ct of 7.38 and 7.05 for sample no. 15
and 7.86 for sample no. 16, cut-off of 8 and c.38GA
(p.Gly13Asp)  Ct of 8.14 and 8.01 for sample no. 17 and 8.59 for
sample no. 18, cut-off of 9). The correlation between the  Ct and
tumour cell percentage for these two mutations is given in Fig. 2.
These four samples (marked as * in Fig. 2) are outliers and are
considered as false positive results of the assay. No correlation
between the  Ct and tumour cell percentage was observed 
(r 0.01 and r 0.038 for c.35GA and c.38GA, respectively).
Also in one of the above mentioned discrepant samples with 
a low tumour cell percentage a c.38GA (p.Gly13Asp) mutation
was observed with a high  Ct of 8.02 (no. 24, marked as  in 
Fig. 2B). As we cannot judge whether the sequence analysis is 
false negative or the assay is false positive, this sample is consid-
ered inconclusive. In two other cases the positive result with the
assay could not be repeated and thus the kit was considered 
false positive (no. 19, 20). In three cases the mutation as detected
in duplicate by the assay could be confirmed in the second
sequence and thus the initial sequence was considered false 
negative (no. 21–23).
Reliability of both tests in samples with low
tumour cell percentages
We observed that KRAS mutations can be missed by sequencing
in samples with a tumour cell percentage below 30%. The distri-
bution of KRAS mutation frequency according to tumour cell
percentage for the assay, sequencing and the most likely final
test result is shown in Fig. 1C. In 4 of the 15 samples (26.7%)
containing 10% or less tumour cells a mutation was detected
with the assay, which is not significantly different from the muta-
tion frequency based on the final test result in samples contain-
ing more than 10% tumour cells (40.5%; P  0.42). However, in
only two of these samples (13.3%) a mutation was detected by
sequencing, which is significantly less than in samples with
more than 10% tumour cells (P  0.035). In samples with 20%
tumour cells still 23% of the KRAS mutations were missed by
sequencing. However, the KRAS mutation frequency in samples
containing 20% or less tumour cells was not statistically signif-
icant different from that of samples with more than 20% tumour
cells (40.2% KRAS mutations) neither by sequencing (27.3%
KRAS mutations, P  0.11), nor by the assay (38.6%, P  0.87).
In samples with 30% tumour cells all 23 mutations are detected
by sequencing.
Test characteristics
Overall, the mutation status of one sample was inconclusive,
sequencing was considered false negative in nine and false posi-
tive in one sample and the kit was considered false negative in
seven and false positive in six samples. A KRAS mutation was
detected in 201 out of 510 samples (39.4%). The prevalence of the
different KRAS mutations is shown in Table 2. The sensitivity of
sequencing and of the real-time PCR-based assay was 95.5%
(95% confidence interval [CI] 91.7–97.9%) and 96.5% (95% CI
93.0–98.6%), respectively. Further characteristics of both tests
are shown in Table 3. Considering the lower sensitivity of sequenc-
ing analysis in samples with less than 30% tumour cells, sensitiv-
ity and specificity of both tests were also calculated in the sub-
group of 398 samples with more than 30% tumour cells, resulting
in a sensitivity of sequencing and the assay of 97.5% (95% CI
93.6–99.3%) and 95.6% (91.1–98.2%), respectively.
Table 2 The distribution of KRAS mutations in 510 samples
N %
c.34G>A (p.Gly12Ser) 8 1.6
c.34G>T (p.Gly12Cys) 20 3.9
c.34G>C (p.Gly12Arg) 5 1.0
c.35G>A (p.Gly12Asp) 67 13.2
c.35G>T (p.Gly12Val) 51 10.0
c.35G>C (p.Gly12Ala) 14 2.8
c.35_36delinsAG (p.Gly12Glu)* 1 0.2
c.37G>T (p.Gly13Cys)* 1 0.2
c.38G>A (p.Gly13Asp)** 33 6.5
c.38_39delinsAG (p.Gly13Glu)* 1 0.2
Total 201 39.4
*Nucleotide changes not covered by the real-time PCR-based assay.
**One of these samples had an additional alteration c.[38G>A; 40G>A]
(p.[Gly13Asp; Val14Ile]).
Table 3 Test characteristics of cycle sequencing and real-time PCR-
based assay for KRAS mutation assessment (n  510)
Cycle Real-time PCR-based
sequencing assay
Sensitivity 95.5% 96.5%
(95% CI) (91.7–97.9%) (93.0–98.6%)
Specificity 99.7% 98.1%
(95% CI) (98.2–100%) (95.8–99.3%)
Positive predictive value 99.5% 97.0%
(95% CI) (97.1–100%) (93.6–98.9%)
Negative predictive value 97.2% 97.7%
(95% CI) (94.7–98.7%) (95.4–99.1%)
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Discussion
In this series of 511 primary colorectal cancer samples we were
able to compare the reliability of KRAS mutation analysis on
FFPE tissue by cycle sequencing and a commercial FDA
approved real-time PCR-based assay. Since a concordant result
between the tests was obtained in over 95% of samples, both
cycle sequencing and the real-time PCR-based assay are reliable
methods for KRAS mutation assessment in colorectal cancer.
Without doing duplicate experiments the KRAS mutation status
was incorrectly determined by cycle sequencing in 2.0% and 
by the commercial assay in 2.6% of the samples. These results
are well below the threshold commonly used in biomarker 
testing [21–23].
Several explanations for the false test results are relevant 
for general clinical practice. First, laboratories offering KRAS
mutation analysis in colorectal cancer should be aware of the
relevance of the tumour cell percentage of material used for
DNA isolation. In samples containing less than 30% tumour
cells KRAS mutations can be missed by cycle sequencing. To
avoid these low tumour cell percentages it is essential to care-
fully select and microdissect the tissue sample used for DNA
isolation. As a low tumour cell percentage is often due to pre-
operative radiotherapy, the reliability of the mutation detection
will in most cases be higher on biopsies that are taken before
the start of radiotherapy. In the rare cases in which a tumour
cell percentage of 30% cannot be reached, the commercial kit
would be the method of choice. We recommend to include the
tumour cell percentage in all reports and to mention the possi-
bility of a false negative result in samples with a tumour cell
percentage below 30%.
Second, the standard  Ct cut-off values of the real-time PCR-
based assay, which are designed to detect 1% mutation in a back-
ground of wild-type DNA might be too high. This might lead to
false positive results. In four samples that were positive in the ini-
tial analysis with the kit, but negative by cycle sequencing, the 
 Ct of that particular mutation was higher than in all other
 samples tested positive. The most likely explanation for these four
discrepant test results is that the assay is false positive, although
tumour heterogeneity with only a small percentage of tumour cells
harbouring a KRAS mutation cannot be formally excluded. In our
series there was no relation between the  Ct and the tumour cell
percentage (Fig. 2), while we had expected to find lower  Ct val-
ues with increasing tumour cell percentages. Although this might
partly reflect variations in tumour heterogeneity or aneuploidy,
also some samples with a very pronounced mutant allele in the
cycle sequencing analysis give relatively high  Ct values, show-
ing that at least part of this variation is due to intrinsic test char-
acteristics. We recommend to register and report both the  Ct
value of the individual analyses and the cut-off value and to assess
the mutation status by cycle sequencing in cases with a  Ct value
approximating the cut-off value.
Third, by the commercial kit only the most abundant KRAS
mutations are detectable. In our series four out of 510 samples
(
1%) were false negative with the assay because the sequence
alterations were not covered by the kit. KRAS mutations located
outside codons 12 and 13 will not be targeted by the assay as well.
Cycle sequencing would allow for detecting mutations other than
those targeted by the kit and circumvents the problem of possible
false positive results due to a high  Ct. On the other hand, the
real-time PCR based kit is the method of choice in samples con-
taining less than 30% tumour cells.
Assessment of KRAS mutation status in FFPE tumour material
is technically more challenging than in fresh frozen tissue due to
DNA fragmentation. However, fresh frozen tissue is usually not
available in routine clinical practice. With the primer set we used
for amplification a product with a length less than 200 bp includ-
ing the M13 sequences was obtained. Both amplification of this
product and of the control amplicon present in the kit were
 successful in 100% of the samples. DNA fragment length thus
was not a limiting determinant in KRAS mutation assessment. We
show that FFPE colorectal cancer tissue derived from many differ-
ent routine pathology laboratories is suitable for KRAS mutation
detection.
Our data show that analysis by both direct sequencing and the
commercial assay provide more optimal results compared to a
single test. However, the relatively small increase in accuracy does
not appear to justify the associated increase in costs. Most dis-
crepancies would be overcome by performing either of the tests in
duplicate, by using the assay in samples with a tumour cell per-
centage below 30% and by sequence analysis of samples with a
higher tumour cell percentage in which the assay results in a high
 Ct. To date, the published data on KRAS mutation assessment
using a real-time PCR-based assay have either been presented as
the result of single testing [10] or with confirmation of all muta-
tions by sequencing [6]. To learn more about the limitations and
interlaboratory reproducibility of these analyses and considering
the expected increase in the use of KRAS testing, a quality assur-
ance program as proposed by the European Society of Pathology
is warranted [15]. A high quality of KRAS testing is important
since false results have major clinical implications. Not only is the
benefit of anti-EGFR therapy restricted to patients with KRAS wild-
type tumours, patients with KRAS mutated tumours may even be
harmed by this treatment [16, 24, 25]. Lastly, data accumulate that
KRAS mutation status is not the only determinant for the efficacy
of anti-EGFR treatment. Other molecular determinants that are
involved in the response to anti-EGFR antibodies, such as BRAF
mutations [26], PIK3CA mutations [27] and EGFR gene copy num-
ber changes [28], may become relevant selection parameters for
this type of treatment.
In conclusion, we show that both cycle sequencing and a
commercial real-time PCR-based assay are reliable tests for
KRAS mutation analysis in FFPE colorectal cancer samples 
provided an adequate percentage of tumour cells is present in the
tissue tested.
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